3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Pancreatic Neoplasms
679
Carcinoma, Non-Small-Cell Lung
324
Neoplasms
168
Breast Neoplasms
163
Urinary Bladder Neoplasms
157
Lung Neoplasms
157
Neoplasm Metastasis
139
Cholangiocarcinoma
112
Ovarian Neoplasms
106
Biliary Tract Neoplasms
92
Lymphoma, Large B-Cell, Diffuse
73
Nasopharyngeal Carcinoma
70
Lymphoma
66
Sarcoma
63
Recurrence
62
Gallbladder Neoplasms
60
Carcinoma, Transitional Cell
55
Triple Negative Breast Neoplasms
54
Hodgkin Disease
52
Colorectal Neoplasms
49
Fallopian Tube Neoplasms
48
Lymphoma, Non-Hodgkin
47
Adenocarcinoma
45
Bile Duct Neoplasms
40
Carcinoma, Ovarian Epithelial
31
Non-Muscle Invasive Bladder Neoplasms
30
Uterine Cervical Neoplasms
28
Carcinoma
28
Unspecified Adult Solid Tumor, Protocol Specific
27
Adenocarcinoma of Lung
27
Interventions
durvalumab
2
tremelimumab
1
ceralasertib
1
aflutinib
1
Radiotherapy
1
Pemetrexed
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Non Small Cell Lung Cancer NSCLC
×
Gemcitabine
×
Clear all
NCT03164616
2026-03-13
POSEIDON
AstraZeneca
Phase 3
Active not recruiting
1,186 enrolled
26 charts
1 FDA